←Back to Expert Scholars
Translational Medicine / 转化医学Cancer Antisense Oligonucleotides
Frank Bennett
PhD
🏢Ionis Pharmaceuticals🌐USA
Executive Vice President and Chief Scientific Officer
90
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Frank Bennett led the development of nusinersen and has overseen the ASO pipeline at Ionis Pharmaceuticals for decades. His work spans basic ASO mechanism and clinical translation including oncology applications. He is a leader in ASO drug development and shared the Breakthrough Prize for SMA therapy.
Share:
🧪Research Fields 研究领域
ASO drug development
nusinersen
SMA therapy
cancer ASO
RNA targeted therapeutics
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Frank Bennett 的研究动态
Follow Frank Bennett's research updates
留下邮箱，当我们发布与 Frank Bennett（Ionis Pharmaceuticals）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment